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BACKGROUND:  Mammary  analog  secretory  carcinoma  (MASC)  was  ﬁrst described  in  2010  by  Skálová
et  al.  This  entity  shares  morphologic  and  immunohistochemical  features  with  the  secretory  carcinoma
(SC)  of  the  breast.  MASC  usually  presents  as  an  asymptomatic  mass  in  the parotid  gland  and  predomi-
nantly  affects  men.  This  tumor  is  considered  a low-grade  carcinoma  but has  the  potential  for  high-grade
transformation.  We  report  one  MASC  case  and  a review  of  world  literature.
CASE  REPORT:  A  66-year-old  male  patient  presented  because  he noticed  a mass  of approximately  3 × 3 cm
on the  right  pre-auricular  region.  Physical  examination  demonstrated  a  3 × 3.5  cm, ﬁrm,  ﬁxed,  non-tender
mass  in the  right  pre-auricular  region.  An  MRI  of the  head  and  neck  showed  an  ovoid  heterogeneous
lesion,  dependent  of the  right  parotid  gland  of 27  ×  28  mm.  We  performed  a superﬁcial  parotidectomy
with  identiﬁcation  and  preservation  of  the  facial  nerve.  The  immunophenotype  was  positive  for  epithe-
lial  membrane  antigen  (EMA),  CK8/18,  vimentin,  S-100  protein,  and  mammoglobin.  No  further  surgical
interventions  or adjuvant  therapies  were  needed.  The  patient  will  have  a  close  follow  up.
CONCLUSION:  The  presence  of  t(12;15)  (p13;q25)  translocation  which  results  in  the  ETV6-NTRK3  gene
fusion  or  positive  immunochemical  studies  for STAT5,  mammoglobin  and  S100  protein,  are  necessary  to
conﬁrm the diagnosis  of  MASC.  MASC  treatment  should  mimic  the  management  of  other  low-grade  malig-
nant  salivary  gland  neoplasms.  The  inhibition  of ETV6-NTRK3  gene  fusion  could  be used as  treatment  in
the future.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Mammary analog secretory carcinoma (MASC) is a newly
escribed carcinoma of the salivary glands, characterized by
orphologic and immunohistochemical features, that strongly
esembles a secretory carcinoma (SC) of the breast [1]. Secretory
arcinoma of the breast (SC) has shown to have a recurrent bal-
nced chromosomal translocation t(12;15) (p13;q25), which leads
o an oncogenic fusion gene ETV6-NTRK3. This translocation is also
resent in MASC [1–3]. This fusion gene encodes a chimeric tyrosine
inase that is known to play an important role on its oncogenesis
3]. Immunohistochemical similarities between MASC and SC of the
reast also include being S100 protein, epithelial membrane anti-
en (EMA), and vimentin positive and “triple negative” (ER/PR/Her2
egative) [4]. MASC predominantly affects men  and normally does
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not behave in an aggressive way [5,6]. The parotid gland is the
most common affected gland by MASC [6,7]. We  present a case
of MASC occurring in a 66-year-old, male, Mexican patient that
manifested an asymptomatic mass in the pre-auricular region. This
article includes information from various case series, in order to
present the best recommendations for the diagnosis and treatment
of this newly described disease. This case report follows the CARE
criteria [8].
2. Case report
We present a 66-year-old male patient with a past medical
history of hypertension, hyperlipidemia, and morbid obesity. Dur-
ing the last months, he experienced an intentional weight loss of
18 kg. Due to the body mass loss, he noticed a mass of approxi-
mately 3 × 3 cm on the right pre-auricular region. A family practice
physician explored the patient and ordered an ultrasound, which
reported a necrotic lymph node. There was no other pertinent
history. Physical examination demonstrated a 3 × 3.5 cm,  ﬁrm,
iates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Neck magnetic resonance imaging of the head and neck showing the right
parotid lesion.
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Fig. 3. Superﬁcial parotidectomy surgical specimen.
Fig. 4. Hematoxylin and eosin staining.Fig. 2. Superﬁcial parotidectomy with preservation of the facial nerve.
xed, non-tender mass on the right pre-auricular region. Facial
erve function was preserved. No palpable lymphadenopathy was
resent on the neck region. A head and neck MRI  showed an
void heterogeneous lesion, dependent of the right parotid gland
f 27 × 28 mm,  hypointense in T1 and isointense in T2 with well-
eﬁned borders and an area of hemorrhage in its interior (Fig. 1).
t was reported as a probable pleomorphic adenoma with hemor-
hagic transformation.
A superﬁcial parotidectomy with identiﬁcation and preserva-
ion of the facial nerve was performed (Fig. 2). The right parotid
land was extracted with a mass of approximately 4 × 4 cm (Fig. 3)
nd a No. 10 Blake drain was inserted. The ﬁnal pathology report
evealed a well-differentiated MASC. The neoplasm substituted the
ormal parotid parenchyma and had well-deﬁned borders. TheFig. 5. Immunohistochemical study for S-100 protein.
tumor had a multinodular rearrangement with nodules divided
by ﬁbrous septa. The nodules showed a microcystic pattern with
papillary structures. The neoplastic cells were medium size, with
predominant eosinophilic cytoplasm (Fig. 4). A dense multivac-
uolated eosinophilic secretion was identiﬁed inside de cysts. The
cellular nucleus was medium size, with smooth borders and homo-
geneous chromatin. There was  no signiﬁcant number of mitoses or
necrotic areas. The immunophenotype was positive for epithelial
membrane antigen (EMA), CK8/18, vimentin, S-100 protein (Fig. 5),
and mammoglobin. There was no expression of p63, CK5/6, DOG1
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Table  1
Characteristics of patients with MASC diagnosis in nine case series.
Case series author Publish year Number of cases Male Female Mean age Age range
Skálová et al. [1] 2010 16 9 7 46 21–75
Connor et al. [4] 2012 7 6 1 40 14–77
Chiosea et al. [17] 2012 10 8 2 45.5 NA
Bishop et al. [2,15] 2013 5 3 2 52 21–78
Grifﬁth et al. [14] 2013 6 3 3 43.7 27–66
Bishop et al. [2,15] 2013 11 4 7 56 20–86
Skálová et al. [5] 2014 3 3 0 63 55–73
Majewska et al. [3] 2014 7 5 2 51.4 17–73
Serrano-Arévalo et al. [18] 2014 4 1 3 50.5 28–83
NA indicates not available.
Table 2
Size, location, and lymph node involvement of MASC in eight case series.
Case series author Number of cases Size (cm) Location
Mean Range Parotid gland Submandibular
gland
Minor salivary
glands in the
buccal mucosa
Lips Palate Lymph node
involvement at
time of diagnosis
Skálová et al. [1,5] 16 2.1 0.7–5.5 13 0 1 1 1 0
Connor et al. [4] 7 1.8 0.5–0.3 2 1 3 1 0 0
Bishop et al. [2,15] 5 1.9 0.8–4.0 4 1 0 0 0 NA
Grifﬁth et al. [14] 6 1.72 1.0–2.5 4 1 1 0 0 1
Bishop et al. [2,15] 11 0.9 0.3–2.0 0 2 1 4 4 0
Skálová et al. [1,5] 3 3.6 3.0–4.0 3 0 0 0 0 1
Majewska et al. [3] 7 2.8 2.0–4.0 6 0 0 0 1 3
Serrano-Arévalo et al. [18] 4 2.6 0.5–7.5 1 1 2 0 0 1
NA indicates non available.
Table 3
Clinical follow up of MASC in six case series.
Case series author Number of cases Clinical follow up
Number of patients with
clinical follow up
Time range (months) Recurrences Dissemination to cervical
lymph nodes
Death
Skálová et al. [1,5] 16 13 3–120 3 1 2
Grifﬁth et al. [14] 6 5 2–6 0 1 0
Bishop et al. [2,15] 11 10 4–85 1 0 0
Skálová et al. [1,5] 3 3 24–72 0 3 3
Majewska et al. [3] 7 7 67–120 2 0 2
Serrano-Arévalo et al. [18] 4 2 10–20 0 1 0
Table 4
Presence of ETV6-NTK3 gene rearrangement and immunohistochemical ﬁndings of MASC in nine case series.
Case series author Number of cases ETV6-NTRK3 gene rearrangement Immunohistochemical ﬁndings
S-100 Vimentin EMA  Mammaglobin STAT5a
Skálová et al. [1,5] 16 13 16 16 9 16 16
Connor et al. [4] 7 7 5 4 NA NA NA
Chiosea et al. [17] 10 10 NA NA NA NA NA
Bishop et al. [2,15] 5 5 NA NA NA NA NA
Grifﬁth et al. [14] 6 3 2 NA NA 1 NA
Bishop et al. [2,15] 11 11 11 NA NA 7 NA
Skálová et al. [1,5] 3 3 3 3 NA 3 NA
Majewska et al. [3] 7 6 7 7 NA 7 7
Serrano-Arévalo et al. [18] 4 3 4 NA NA 4 4
NA indicates non available.
Table 5
Treatment of MASC in different case series.
Case series author Number of cases Treatment
Conservative
parotidectomy
Non-radical
parotidectomy
Resection of the
tumor
Radical
parotidectomy
Radiotherapy Neck
dissection
Chemotherapy
Skálová et al. [1,5] 16 3 10 0 3 7 1 0
Connor  et al. [4] 7 7 0 0 0 3 2 0
Grifﬁth  et al. [14] 6 3 0 2 0 0 3 0
Bishop  et al. [2,15] 11 0 11 0 0 0 1 0
Skálová  et al. [1,5] 3 1 2 0 0 3 1 1
Majewska et al. [3] 7 5 1 1 0 3 2 1
Serrano-Arévalo et al. [18] 4 0 1 1 0 1 1 NA
NA indicates non available.
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r zymogen granule formation. The surgical margins were negative
or malignancy.
The ﬁnal diagnosis was  MASC staged as a pT2, cN0, cM0, stage
I, R0 salivary carcinoma. The patient presented slight facial nerve
ysfunction (grade II House–Brackmann facial nerve grading sys-
em), that recovered approximately one month after surgery. The
lake drain was removed on the twelfth day after the procedure.
fter discussing the case in our multidisciplinary tumor board, no
urther surgical intervention (total parotidectomy or selective neck
issection) or adjuvant therapy (radiation) was recommended. The
atient will have a close follow up that would entail a complete his-
ory and physical examination every 3 months for the ﬁrst 5 years.
here is no evidence of persistent or recurrent disease 4 months
ost-surgery and the facial nerve function is back to baseline.
MASC was ﬁrst described in 2010 by Skálová et al. in a clin-
copathologic study of a series of 16 salivary gland tumors with
istomorphologic and immunohistochemical features similar to SC
f the breast [1]. One of the principal similarities between MASC
nd SC of the breast is the presence of the translocation t(12;15)
p13;q25), that results in the formation of the oncogenic fusion
ene ETV6-NTK3 [1–4], which is also present in other tumors
uch as infantile ﬁbrosarcoma [3,4,9], myelogenous leukemia [3],
nd congenital mesoblastic nephroma [1,3,4,10]. The fusion of the
ranscriptional regulator gene ETV6 and the membrane receptor
inase-type NTRK3 results in a chimeric tyrosine kinase that acti-
ates cell proliferation and increases survival of the tumor cells
laying a fundamental role on its oncogenesis [3,11]. MASC and
C of the breast also share immunohistochemical features such as
eing positive for S100 protein, EMA, and vimentin, while being
triple negative” (ER/PR/Her2 negative) [4].
The most important differential diagnosis for MASC is the ACC
3]. ACC is characterized by the presence of large, serous, acinar
ells with cytoplasmatic PAS positive zymogen-like granules that
re absent in MASC [1,12]. MASC is histologically characterized by
he proliferation of uniform eosinophilic cells with a vacuolated
ytoplasm, growing within a microcystic, macrocystic, and pap-
llary architecture [13–15]. Even though the similar growth rate
etween MASC and ACC, MASC is more likely to metastasize to the
egional lymph nodes, it should be considered as a more aggressive
umor compared with the regular low grade ACC [16].
MASC has a slight preference for male patients while ACC
ainly affects women [7]. In Table 1, we state the gender pref-
rences of MASC from nine case series published between 2010
nd 2014. Immunophenotypic features that can be used to differ-
ntiate MASC from ACC are the expression of protein S100 and
ositive mammaglobin staining [3]. S100 is strongly positive in
ASC, while it is negative in ACC [17]. Immunohistochemistry is
lso helpful in differentiating SDC from MASC because SDC nor-
ally expresses androgen receptors or HER-2/neu and not S100
rotein [3]. Vimentin, STAT5a and cytokeratin 7 are other important
mmunohistochemical markers present in MASC [7]. MASC has also
een misdiagnosed as cystadenocarcinoma because of the cystic
omponent that is sometimes present [4].
MASC usually presents as a painless, non-tender mass that
ncreases in size overtime [1,18]. The majority of MASC arise from
he parotid gland, accounting for two thirds of the reported cases
2]. Table 2 presents the location, size, and lymph node involvement
f MASC in eight case series. Bishop found that the mean age for pre-
entation of MASC is 47 years (Table 2), in contrast with SC of the
reast that usually occurs in younger patients [19]. MASC is consid-
red a low-grade carcinoma with a favorable prognosis; according
o Skálová et al. it has moderate risk for local recurrence (15%),
ymph node metastases (20%), and a low risk for distant metas-
ases (5%) [1,5]. In Table 3 we present the clinical follow up of six
ase series. There have been reports of high-grade transformation
n MASC in which it becomes a far more aggressive tumor with anPEN  ACCESS
gery Case Reports 16 (2015) 187–191
accelerated clinical course that results in cancer dissemination and
death [5].
The deﬁnite diagnosis of MASC is done by conﬁrming the
translocation t(12;15) (p13;q25), which results in the ETV6-NTRK3
gene fusion [15]. However, a negative test for ETV6-NTRK3 gene
fusion does not rule out the diagnosis of MASC [1,18], it can also be
done with the presence of positive immunohistochemical studies
for STAT5, mammoglobin, and S-100 protein [16,18]. We  revised
the data from different case series regarding the presence of ETV6-
NTK3 gene rearrangement and the immunohistochemical ﬁndings
of MASC and stated it on Table 4.
The treatment of MASC is not well deﬁned because most studies
in the literature are retrospective in nature [19]. The reported dis-
ease free period for MASC ranges from 71 to 115 months, shorter
than the one reported in ACC, which is 92–148 months [16]. Table 5
presents different treatment alternatives that have been used for
MASC. The treatment of choice in high-grade transformation MASC
should be radical surgery with neck dissection in addition to adju-
vant radiotherapy [5]. In the future, the inhibition of ETV6-NTRK3
may become a therapeutic target for patients with MASC as for
other tumors that express this mutation (Table 5) [20].
3. Conclusion
MASC is a salivary gland tumor ﬁrst described in 2010, which is
characterized by histologic, immunophenotypic, and genetic sim-
ilarities to SC of the breast. MASC and SC of the breast share the
t(12;15) (p13;q25) translocation which results in the ETV6-NTRK3
gene fusion, they are also both positive for S100 protein, EMA,
and vimentin and “triple negative” (ER/PR/Her2). Conﬁrming the
presence of ETV6-NTRK3 gene fusion or positive immunochemical
studies for STAT5, mammoglobin and S100 protein are necessary to
conﬁrm the diagnosis. MASC is considered a low-grade carcinoma
with a favorable prognosis, so at this time, treatment should mimic
the management of other low-grade malignant salivary gland neo-
plasms. When high-grade transformation occurs, a more aggressive
multidisciplinary management should be undertaken because of its
poor prognosis. The inhibition of ETV6-NTRK3 gene fusion could be
used as treatment in the future.
Conﬂicts of interest
None.
Funding
None.
Ethical approval
There was no need for ethical approval.
Author contributions
Balanzá Ricardo: Writing, and data analysis.
Mun˜oz Manuel: Data collection.
Moreno Eduardo: Data collection.
Luque Enrique: Data collection.
Cordera Fernando: Data collection.
Arrangoiz Rodrigo: Data analysis, writing, and study design.
Toledo Carlos: Data collection.
Gonzalez Edgar A: Data collection.
 –  O
 of Sur
G
R
[
[
[
[
[
[
[
[
[
[
[
O
T
p
cCASE  REPORT
R. Balanzá et al. / International Journal
uarantors
Balanzá Ricardo
Arrangoiz Rodrigo
eferences
[1] A. Skálová, T. Vanecek, R. Sima, et al., Mammary analogue secretory
carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a
hitherto undescribed salivary gland tumor entity, Am.  J. Surg. Pathol. 34
(2010) 599–608.
[2] J. Bishop, R. Yonescu, D. Bastista, et al., Most nonparotid actinic cell
carcinomas represent mammary analog secretory carcinomas, Am.  J. Surg.
Pathol. 37 (2013) 1053–1057.
[3] H. Majewska, A. Skálová, D. Stodulski, et al., Mammary analogue secretory
carcinoma of salivary glands: a new entity associated with ETV6 gene
rearrangement, Virchows Arch. (2014), http://dx.doi.org/10.1007/s00428-
014-1701-8.
[4] A. Connor, B. Perez-Ordon˜ez, M.  Shago, et al., Mammary analog secretory
carcinoma of salivary gland origin with the ETV6 gene rearrangement by
FISH: expanded morphologic and immunohistochemical spectrum of a
recently described entity, Am. J. Surg. Pathol. 36 (2012) 27–34.
[5] A. Skálová, T. Vanecek, H. Majewska, et al., Mammary analogue secretory
carcinoma of salivary glands with high-grade transformation report of 3 cases
with the ETV6-NTRK3 gene fusion and analysis of TP53, beta-catenin, EGFR,
and  CCND1 genes, Am.  J. Surg. Pathol. 38 (2014) 23–33.
[6] P. Levine, K. Fried, L. Krevitt, et al., Aspiration biopsy of mammary analogue
secretory carcinoma of accessory parotid gland: another diagnostic dilemma
in  matrix-containing tumors of the salivary glands, Diagn. Citopathol. 42
(2012) 49–53.
[7] N. Kuroda, K. Miyazaki, M.  Michal, Small mammary analogue secretory
carcinoma arising from minor salivary gland of buccal mucosa, Int. Cancer
Conf. J. (2014), http://dx.doi.org/10.1007/s13691-014-0172-8.[8]  and the CARE GroupJ. Gagnier, G. Kienle, D.G. Altman, D. Moher, H. Sox, D.S.
Riley, The CARE guidelines: consensus-based clinical case report guideline
development, J. Clin. Epidemiol. 67 (1) (2013) 46–51.
[9] S.R. Knezevich, D.E. McFadden, W.  Tao, et al., A novel ETV6-NTRK3 gene fusion
in  congenital ﬁbrosarcoma, Nat. Genet. 18 (1998) 184–187.
pen Access
his article is published Open Access at sciencedirect.com. It is distrib
ermits unrestricted non commercial use, distribution, and reproduct
redited.PEN  ACCESS
gery Case Reports 16 (2015) 187–191 191
10] B.P. Rubin, C.J. Chen, T.W. Morgan, et al., Congenital mesoblastic nephroma
t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and
molecular relationship to congenital (infantile) ﬁbrosarcoma, Am.  J. Pathol.
153 (1998) 1451–1458.
11] S.R. Knezevich, M.J. Garnett, T.J. Pysher, B. Beckwith, P. Grundy, P. Sorensen,
ETV6-NTRK3 gene fusion and trisomy 11 establish a histogenetic link
between mesoblastic nephroma and congenital ﬁb-rosarcoma, Cancer Res. 15
(1998) 5046–5048.
12] G.L.A. Ellis, P.L. Auclair, Acinic cell adenocarcinoma, in: G.L.A. Ellis, P.L. Auclair
(Eds.), AFIP Atlas of Tumor Pathology: Tumors of the Salivary Glands, ARP
Press, Washington, D.C, 2008, pp. 204–224.
13] M.  Hirokawa, K. Sugihara, T. Sai, et al., Secretory carcinoma of the breast: a
tumour analogous to salivary gland acinic cell carcinoma? Histopathology 40
(2002) 223–229.
14] C. Grifﬁth, E. Stelow, A. Saqi, et al., The cytological features of mammary
analogue secretory carcinoma a series of 6 molecularly conﬁrmed cases,
Cancer Cytopathol. 121 (2013) 234–241.
15] J. Bishop, R. Yonescu, D. Batista, et al., Cytopathologic features of mammary
analogue secretory carcinoma, Cancer Cytopathol. 121 (2013) 228–233.
16] S.I. Chiosea, C. Grifﬁth, A. Assaad, R.R. Seethala, Clinicopathological
characterization of mammary analogue secretory carcinoma of salivary
glands, Histopathology 61 (2012) 387–394.
17] S. Chiosea, C. Grifﬁth, et al., The proﬁle of acinic cell carcinoma after
recognition of mammary analog secretory carcinoma, Am.  J. Sug. Pathol. 36
(2012) 343–350.
18] M.L. Serrano-Arévalo, A. Mosqueda-Taylor, H. Domínguez-Malagón, M.
Michal, Mammary analogue secretory carcinoma (MASC) of salivary gland in
four mexican patients, Med. Oral Patol. Oral Cir. Bucal. (2014), http://dx.doi.
org/10.4317/medoral.19874.
19] J. Bishop, Unmasking MASC: bringing to light the unique morphologic,
inmunohistochemical and genetic features of the newly recognized
mammary analogue secretory carcinoma of salivary glands, Head Neck
Pathol. 7 (2013) 35–39.
20] C.E. Tognon, A.M. Somasiri, V.E. Evdokimova, et al., ETV6-NTRK3-mediated
breast epithelial cell transformation is blocked by targeting the IGF1R
signaling pathway, Cancer Res. 71 (2011) 1060–1070.uted under the IJSCR Supplemental terms and conditions, which
ion in any medium, provided the original authors and source are
